A Early Phase 1 Clinical Trial To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Latest Information Update: 20 Dec 2022
At a glance
- Drugs Anti-CD19-DASH-chimeric-antigen-receptor-T-cell-therapy-Hrain-Biotechnology (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Hrain Biotechnology
Most Recent Events
- 20 Dec 2022 New trial record